Novel SH2-​containing inositol 5-​phosphatase (SHIP 1) modulator

Selective blocker of the Aquaporin-1 ion channel conductance, slowing cancer cell migration

Inactive analog of pyrabactin used as the negative controller

Prodrug of APX-001A, the first-in-class inhibitor of the fungal protein Gwt1

First-in-class inhibitor of APS reductase (APSR), a critical enzyme in the assimilation of sulfate for the biosynthesis of cysteine and other essential sulfur-containing molecules

Novel tumor calibrated inhibitor, showing unique polypharmacology and strongly improved therapeutic index in fly and human MTC xenograft models

Marine-Derived Peptidic Stimulator of VEGF-A and Other Growth Factors with Potential Application in Wound Healing

Aminoglycoside antibiotic used in veterinary medicine

Novel anticancer agent, arresting MCF-7 cell growth at G2/M phase and S phase, dose dependent increasing in the mitochondrial membrane potential (ΔΨm) and ROS levels, decreasing in Gal-1 protein levels

Novel inducer of cell death by activating apoptosis in cancer cells

Inhibitor of HMG-CoA-reductase, promoting apoptosis of myeloma cells in vitro

Potent inhibitor of Bcl-2 and Mcl-1, acting as a BH3 mimetic

Novel apolipoprotein E4 (apoE4) stabilizer, showing activity in an IL-6 and IL-8 cytokine release assay

Novel inducer of endogenous ApoA-I, protecting against atherosclerotic lesion development in ApoE-/- mice, upregulating the apolipoprotein A-I gene expression, enhancing its function of promoting cholesterol efflux, ABCA1 expression and activation of PPAR

Novel extremely potent inhibitor of APN activity in vitro, selective against other zinc-dependent enzymes such as matrix metalloproteases, and possessed limited cytotoxicity against Ad293 cells and favorable physicochemical and metabolic stability propert

Potent aminopeptidase N/CD13 (APN) inhibitor

Histamine H3 receptor antagonist

Novel inhibitor of PCAF bromodomain/Tat-AcK50 association

Selective A2a adenosine receptor agonist

Novel inhibitor of PCAF bromodomain/Tat-AcK50 association

Novel inhibitor of the Ap4A phosphorylase (Rv2613c) of Mycobacterium tuberculosis (Mtb)

Potent and selective antitumor agent, effectively depleting cellular Fe, resulting in transferrin receptor-1 up-regulation, ferritin down-regulation, and increased expression of the potent metastasis suppressor, N-myc downstream regulated gene-1

Novel inhibitor of the gatekeeper mutant of BCR-ABL, suppressing in vitro resistance

Novel highly potent and selective Src_%28gene%29>Src kinase inhibitor

Inhibitor of both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation

Novel highly potent and selective α4β2 nAChR antagonist

Cyclooxygenase inhibitior

Novel tumor-targeting cytotoxic agent

Novel anticancer agent, targeting PPARγ and HDAC4, being cytotoxic to CCRF-CEM cells (CC50 = 2.8 μM), inducing apoptosis, and causing DNA fragmentation, modulating the expression of c-Myc, cleaving caspase-3, and causing in vivo tumor regression in CCRF-C

Novel cellular anticancer agent, exhibiting 7.9-341.7-fold antiproliferative activities against four cell lines, Aspc-1 (human colon adenocarcinoma cells), H358 (human nonsmall cell lung cancer cells), HCT116 (human colorectal adenocarcinoma cells), and S